Project Oncology®
Health, Fitness & Longevity
About
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
Episodes
- ReDiscover-2: Currently Enrolling Patients With PIK3CA-Mutated Advanced Breast Cancer
The ReDiscover-2 trial is currently enrolling patients with PIK3CA-mutated advanced breast cancer who have progressed after CDK4/6 inhibitor therapy. Dr. Sarah Sammons and Dr. Charles Turck review findings from the ReDiscover trial support…
- Addressing Barriers to CAR T Referral in R/R LBCL
This episode of Project Oncology® discusses challenges in referring patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) for CAR T-cell therapy. Host Steve Jackson speaks with guests Matthew J. Matasar and Tycel Phillips a…
- Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Dr. Charles Turck and Dr. Petros Grivas discuss the role of urinary and circulating tumor DNA (ctDNA) in muscle-invasive bladder cancer, referencing data from the NIAGARA trial. They explore how perioperative durvalumab affects ctDNA clear…
- ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Dr. Charles Turck and Dr. Guru Sonpavde discuss findings from the IMvigor011 study presented at the 2026 ASCO Genitourinary Cancers Symposium. They explore how ctDNA monitoring in muscle-invasive bladder cancer (MIBC) can detect early recu…
- ctDNA-Guided Bladder Preservation in Muscle-Invasive Bladder Cancer
Dr. Pooja Ghatalia joins host Charles Turck to review findings from the RETAIN trials on ctDNA-guided bladder preservation for muscle-invasive bladder cancer. The discussion covers how ctDNA clearance correlates with improved metastasis-fr…
- Expanding Access to CAR T-Cell Therapy in R/R Myeloma Care
Host: Brian P. McDonough, MD, FAAFP Guest: Tara Graff, DO, MS Guest: Surbhi Sidana, MD This is a non-certified educational series produced and controlled by ReachMD. While BCMA-directed CAR T-cell therapy has changed the treatment landscap…
- Tracking Treatment Response: ctDNA Insights in MMR-p Colon Cancer
Host: Brian P. McDonough, MD, FAAFP Guest: Christopher T. Chen, MD What if a simple blood draw could reveal whether a patient is responding to treatment before surgery? That question is at the heart of a study presented at the 2025 ESMO Co…
- How the 2025 IMWG Guidelines are Reshaping Sequencing in R/R Multiple Myeloma
Host: Jennifer Caudle, DO, FACOFP Guest: Mansi R. Shah, MD This is a non-certified educational series produced and controlled by ReachMD. The latest International Myeloma Working Group (IMWG) guidelines emphasize immune function, relapse t…
- How the First Metastatic Site Shapes Survival in Breast Cancer Relapse
Presenter: Ryan Quigley Not all metastatic breast cancer is created equal. This AudioAbstract spotlights new data from a multicenter study in Japan that highlights how the first site of distant recurrence can significantly shape a patient’…
- Advancing HER2-Targeted Therapy in GI Cancers
Guest: John H. Strickler, MD The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. John Strickler joins…
- How AI Is Transforming Biomarker Development in GI Oncology
Guest: William Hall, MD From tumor detection to biomarker development, artificial intelligence (AI) is rapidly reshaping the landscape of gastrointestinal oncology. In this expert-led program, Dr. William Hall explains how AI is being appl…
- Surgical Insights on Gastroesophageal Cancer: Balancing Surveillance and Intervention
Guest: Daniela Molena, MD For patients with locally advanced gastroesophageal cancer, surgery remains a critical component of curative treatment—even in the era of chemoradiation and advanced imaging. Dr. Daniela Molena explores the challe…
- ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Andrea Necchi, MD Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive…
- From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Guest: Seth Wander, MD, PhD Over the past decade, CDK4/6 inhibitors have transformed the treatment landscape for HR+ breast cancer, but resistance remains a key clinical challenge. Hear from Dr. Seth Wander as he explores the latest transl…
- Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Host: Pavani Chalasani, MD, MPH Guest: Timothy Yap, MBBS, PhD, FRCP Early findings from the PETRA study suggest that combining saruparib with camizestrant may offer added clinical benefit in ER+/HER2– advanced breast cancer, particularly i…
- Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Host: Brian P. McDonough, MD, FAAFP Guest: Matthew Galsky, MD Five years after treatment, the impact of adjuvant nivolumab still holds strong in high-risk muscle invasive urothelial carcinoma. Join Drs. Brian McDonough and Matthew Galsky a…
- Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Host: Ryan Quigley Guest: Kathrin M. Bernt, MD Guest: Rushabh Mehta, BS Guest: Fatemeh Alikarami New data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition reveals how chemotherapy and immunotherapy may dr…
- Unmet Needs in Endometrial Cancer: Bridging Gaps in Treatment and Equity
Guest: Brian Slomovitz, MD Endometrial cancer is rising in incidence, with mortality now surpassing that of ovarian cancer. Hear from Dr. Brian Slomovitz as he explores evolving molecular classifications, treatment challenges, and the urge…
- Reducing Endometrial Cancer Risk: Targeting Modifiable Risk Factors
Guest: Brian Slomovitz, MD Endometrial cancer is closely tied to modifiable risk factors such as obesity, diabetes, hypertension, and insulin resistance—all components of a chronic inflammatory state that heightens cancer susceptibility. D…
- Beyond the Cure: Addressing Psychosocial Needs in Gene Therapy for SCD
Guest: Victoria Coleman-Cowger, PhD Gene therapy offers transformative potential for individuals with sickle cell disease, but the psychosocial challenges that accompany such a major decision are often underestimated. Hear from Dr. Victori…
- Modern Era, New Outcomes: Survival Trends in Breast Cancer Brain Metastases
Host: Ryan Quigley How are patients with breast cancer brain metastases faring in the modern treatment era? In this AudioAbstract, Ryan Quigley shares findings from a 25-year review of 507 patients at UCSF, providing new insights into how…
- Targeting Ribosome Maturation: A Preclinical Strategy for Triple-Negative Breast Cancer
Host: Ryan Quigley Triple-negative breast cancer (TNBC) remains one of the hardest subtypes to treat, with limited options and high relapse rates—so identifying new therapeutic targets is critical. In this AudioAbstract, Ryan Quigley spotl…
- CLL17 Trial Insights: Fixed-Duration vs Continuous Therapy in Frontline CLL
Guest: Ryan Quigley At the 2025 American Society of Hematology Annual Meeting and Exposition, researchers presented key findings from the pivotal phase three CLL17 trial, which was the first randomized study to directly compare continuous…
- Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
As medicine shifts toward race-neutral lung function interpretation, new challenges emerge in ensuring equitable access to care. Dr. Ajay Sheshadri explores how race-neutral spirometry may impact patient selection for lung resection surger…
- Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Race-based spirometry adjustments have long influenced pulmonary risk assessments, often underestimating disease severity in Black patients. Hear from Dr. Ajay Sheshadri as he examines the historical misuse of race in lung function testing…
- Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
A 2025 study in Chest evaluated PREDICT, a precision medicine program at a large academic-community practice, designed to streamline testing and expand access to personalized treatment for non-small cell lung cancer (NSCLC). Hear from Reac…
- Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease
Guest: Alexis Leonard Sickle cell disease management traditionally involves two primary treatment approaches: disease-modifying therapies and curative strategies. While disease-modifying therapies can help reduce complications associated w…
- Evaluating Gene Therapy for Sickle Cell Disease: Advantages and Barriers
Guest: David Jacobsohn Gene therapy is redefining the treatment landscape for sickle cell disease, with approaches like gene addition, gene editing, and fetal hemoglobin induction showing promise in reducing or even eliminating symptoms. H…
- CRISPR in Sickle Cell: Transforming Care Through Gene Editing
Guest: Alexis Leonard CRISPR technology, while relatively new, has shown potential in treating patients with sickle cell disease by increasing fetal hemoglobin. Though this gene therapy comes with safety considerations, refinements and adv…
- Curative Strategies for Sickle Cell Disease: The Future of Gene Editing
Guest: Alexis Leonard With two FDA-approved gene therapies, including the first CRISPR-based treatment, curative strategies for sickle cell disease are continuing to expand the treatment landscape. However, challenges remain in optimizing…
- Examining Barriers and Facilitators in Pediatric Sickle Cell Disease Care
Host: Ashley Baker, MSN, PMHNP Guest: Alyssa Schlenz Guest: Shannon Phillps Families of children with sickle cell disease have noted both an abundance of support and significant obstacles when accessing care, ranging from knowledgeable pro…
- Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learni…
- Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronexta…
- Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Host: Marlene Mimi Maeusli, PhD. A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, par…
- Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Guest: Paola Marignani, PhD, EMBA While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Pao…
- From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this…
- The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. J…
- Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he di…
- Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani…
- Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay
Host: Ryan Quigley Guest: Hallie Blevins, PhD. Guest: Marlene Mimi Maeusli, PhD. With one in three eligible Americans still unscreened for colorectal cancer (CRC), there’s an urgent need for noninvasive and affordable alternatives to colon…
- Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies
Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that…
- Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
Guest: Abiodun Ologunowa Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive…
- Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies
Guest: Yogindra Persuad Despite the promise of curative therapies for sickle cell disease, access and cost barriers highlight the ongoing need for disease-modifying treatments like hydroxyurea. Tune in to hear Dr. Yogindra Persuad, a physi…
- Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Guest: Parul Rai Hydroxyurea and chronic transfusions remain cornerstone therapies in managing sickle cell disease, with proven benefits in reducing stroke risk and improving anemia. However, considerations remain, including their impact o…
- Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Guest: Yogindra Persuad For decades, hydroxyurea has been the cornerstone therapy for sickle cell disease, but new disease-modifying therapies, curative strategies, and gene therapies are expanding options for patients. While these advanci…
- The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Guest: Nidhi Bhatt Effective transition from pediatric to adult care should begin as early as age twelve for patients with sickle cell disease, incorporating factors like education, self-advocacy skills, and support from transition care co…
- Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Guest: Parul Rai Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these iss…
- Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Guest: Jorge Nieva, MD As cancer treatment continues to evolve, at-home subcutaneous immunotherapy is at the forefront of decentralized care and research. Here to share his insights on how this delivery model could impact clinical trials a…
- Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Guest: Jorge Nieva, MD As immunotherapy becomes a cornerstone for treating a growing number of solid tumors, reducing the logistical burden of in-office care is essential. Fortunately, the at-home administration of subcutaneous formulation…
- Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Guest: Jorge Nieva, MD Despite the promising benefits for cancer patients, the at-home administration of subcutaneous immunotherapy poses complex operational and logistical challenges, like cost, payer preferences, and patient safety. Tune…